» Articles » PMID: 17596522

Aldosterone Induces Epithelial-mesenchymal Transition Via ROS of Mitochondrial Origin

Overview
Specialties Nephrology
Physiology
Date 2007 Jun 29
PMID 17596522
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

It has been well appreciated that aldosterone (Aldo) plays a direct profibrotic role in the kidney but the underlying mechanism is unclear. We examined the role of Aldo in epithelial-mesenchymal transition (EMT) both in vitro and in vivo. Exposure of human renal proximal tubular cells to Aldo for 48 h dose dependently induced EMT as evidenced by conversion to the spindle-like morphology, loss of E-cadherin, and de novo expression of alpha-smooth muscle actin (SMA); the effect was noticeable at 50 nM and maximal at 100 nM. The EMT was completely blocked by the selective mineralocorticoid receptor (MR) antagonist eplerenone. Aldo time dependently increased intracellular reactive oxygen species (ROS) production that was detectable at 15 min and peaked (2.3-fold) at 60 min, as assessed by 2',7'-dichlorofluorescin diacetate fluorescence. Aldo-induced oxidative stress and EMT were both abolished by the mitochondrial respiratory chain complex I inhibitor rotenone, but not the NADPH oxidase inhibitor apocynin. Aldo induced phosphorylation of ERK1/2 that was completely blocked by rotenone. Male 129-C57/BL6 mice were treated with deoxycorticosterone acetate (DOCA) salt (subcutaneous implantation of 50 mg of DOCA pellet plus 1% NaCl as drinking fluid) for 3 wk and animals were treated with vehicle or rotenone (600 ppm in diet) for the last week. DOCA salt induced a 2.5-fold increase in alpha-SMA and a 30% reduction of E-cadherin, as assessed by real-time RT-PCR, that were both restricted to renal epithelial cells, as determined by immunohistochemistry. In contrast, DOCA salt-induced changes in alpha-SMA and E-cadherin were completely blocked by treatment with rotenone. These observations suggest that Aldo induces EMT via MR-mediated, mitochondrial-originated, ROS-dependent ERK1/2 activation in renal tubular epithelial cells.

Citing Articles

Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study.

Zhou L, Li W Int Urol Nephrol. 2024; 56(12):3877-3885.

PMID: 38985246 PMC: 11534878. DOI: 10.1007/s11255-024-04142-1.


Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives.

Wang Y, Jin M, Cheng C, Li Q Front Endocrinol (Lausanne). 2023; 14:1238927.

PMID: 37600689 PMC: 10433744. DOI: 10.3389/fendo.2023.1238927.


Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.

Liu W, Yu S Kidney Dis (Basel). 2023; 9(1):12-25.

PMID: 36756081 PMC: 9900468. DOI: 10.1159/000528066.


Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.

Soares M, Goncalves R, Vasques J, da Silva-Junior A, Gubert F, Santos G Front Mol Neurosci. 2022; 15:883378.

PMID: 35782379 PMC: 9244712. DOI: 10.3389/fnmol.2022.883378.


Sirtuins and Hypoxia in EMT Control.

Aventaggiato M, Barreca F, Sansone L, Pellegrini L, Russo M, Cordani M Pharmaceuticals (Basel). 2022; 15(6).

PMID: 35745656 PMC: 9228842. DOI: 10.3390/ph15060737.